SM04690, an intra-articular injection for knee OA, will soon enter phase 3 trials to assess its effects on pain, joint function and disease…
Search results for: hospital
Galectin-3 May Be a Biomarker for Cardiovascular Disease in RA
Galectin-3 may have potential as a biomarker for the early onset of cardiovascular disease in RA patients, potentially enabling early intervention and deferring the cardiovascular risks associated with RA…
MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA
New research does not support the use of a magnetic resonance imaging (MRI)-guided strategy for treating RA patients. The study found that among RA patients in remission, an MRI-guided treat-to-target strategy compared with a conventional treat-to-target strategy did not result in improved disease activity remission rates or reduced radiographic progression…
Knee Replacement in Younger Patients Has Higher Complication Rate
NEW YORK (Reuters Health)—Total knee replacement (TKA) is increasingly being performed in younger patients, and new research suggests that these patients have a higher risk for complications than older patients. “The number of knee replacements we are doing in younger and younger patients keeps increasing every year and we need to let these patients know…
Joining Forces to Advance Pediatric Rheumatology Care
Pediatric rheumatologists are in high demand. In fact, a shortage of pediatric rheumatologists requires more than half of all U.S. children with rheumatic diseases seek care with adult rheumatologists, and this shortage is projected to increase. For the past decade, the ACR’s Special Committee on Pediatric Rheumatology has worked to change this by bringing together…
FDA Approves Guselkumab Injector
The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…
To Bridge Health Disparities, Diagnose Lupus Early & Improve Access
CHICAGO—At the 2018 ACR/ARHP Annual Meeting, rheumatologist project volunteers for the ACR’s Collaborative Initiatives talked about their efforts to educate primary-care providers, patients and families in their communities about systemic lupus erythematosus (SLE). Their goal is to facilitate timely diagnosis and treatment of lupus, especially in underserved communities. Health Disparities Health disparities, or differences in health…
Draft Classification Criteria for IgG4-Related Disease Introduced
CHICAGO—John H. Stone, MD, MPH, director of clinical rheumatology at Massachusetts General Hospital, Boston, took the stage at the 2018 ACR/ARHP Annual Meeting to present, for the first time, a draft of new classification criteria for IgG4-related disease (IgG4-RD), a project supported by both the ACR and EULAR. Even though it was the last day…
Biosimilars: How Do They Affect Patient Care & Safety?
CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center…
Antiphospholipid Antibody Syndrome: Much Remains to be Learned
CHICAGO—Antiphospholipid antibody syndrome (APS) mainly affects young women, but can also affect men. APS patients test positive for multiple antibodies, including lupus anticoagulant (LAC), anti-cardiolipin and/or anti-beta2-glycoprotein I. These antibodies are diagnostic of APS, and they place the patient at increased risk for thrombosis and, in women, pregnancy morbidity. Women with LAC or those who…
- « Previous Page
- 1
- …
- 128
- 129
- 130
- 131
- 132
- …
- 323
- Next Page »